News
Article
Author(s):
Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025. Using these responses, we have compiled a list of dermatological meetings taking place this year.
The FDA approval in November 2024 of 40-mg minocycline hydrochloride (Emrosi; Journey Medical Corporation), formerly known and hereafter referred to as DFD-29, marked a significant step forward in the treatment of rosacea.
The approval of these 40-mg extended-release capsules represents the first time an oral, systemic therapy has been given the green light in the US to address both erythema and inflammatory lesions—2 hallmark symptoms of rosacea. Here, Dermatology Times looks back at DFD-29’s journey to approval and its future role in the rosacea treatment landscape.
Hair care is, without a doubt, the trendiest of all areas of dermatology! Because hair is nonliving, it does not fall under any governmental regulation, so creativity is the name of the game, and the wilder the better. However, the rapidly changing hair care market is important to the dermatologist, because we are indeed the hair experts. To keep you abreast of hair care trends, Zoe Diana Draelos, MD, examined 3 of the most popular hair care ideas for 2025.
Eirion Therapeutics announced positive results for its first-in-man clinical trial of topical ET-02 in the treatment of androgenic alopecia. The drug was safe and well-tolerated, with unprecedented results being observed as early as 5 weeks.
Dermatology Times spoke with Jon Edelson, MD, CEO and President of Eirion. He shared groundbreaking insights into the therapeutic potential of ET-02, its mechanism of action, and how it aims to revolutionize the treatment landscape for hair loss.
At the inaugural Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed how NPs and PAs can advance their professional growth by seizing opportunities to share their clinical experiences.
“Include us in ad boards. Include us in publishing. Include us in poster creation. We want to be able to do all the things that our MD counterparts are doing. We’re not trying to be them, but we want to rub shoulders with them. We want to have the same chances to grow professionally that they have,” DiRuggiero said in an interview with Dermatology Times at the meeting held in Las Vegas, Nevada.